Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand

Transcript intelligence

What changed

Management reported 9% growth in portfolio receipts and 12% year-to-date growth in royalty receipts, citing royalties including Zoryve and Mimrylo and performance from existing assets such as Imdelltra. It also highlighted $1 billion of R&D co-funding deals announced in 2026. Compared with Q2, the call described continued receipt growth, further acquisitions and another guidance increase; the supplied analysis does not give the new guidance range.

Guidance delta

Full-year guidance was raised for the third consecutive quarter. The supplied analysis does not specify the revised range or the size of the increase.

Key takeaways

• Reported portfolio receipts grew 9%; year-to-date royalty receipts grew 12%.
• Management cited new royalties and existing-asset performance as growth contributors.
• R&D co-funding was presented as an expanding source of deal activity.
• The guidance raise is positive, but its magnitude cannot be assessed from the supplied analysis.

Management priorities

• Pursue royalty acquisitions, emphasizing first-in-class and best-in-class assets.
• Scale R&D co-funding partnerships across therapeutic areas.
• Use AI in deal sourcing and portfolio analytics, while expanding China presence.